Patrice Hugo, Ph.D. | February 09, 2018

Third Party Component Operational Aspects of PDL1 Stratification and Biomarkers

Immuno-Oncology 360° Conference Presentation
Presented during the Immuno-Oncology 360° conference, this presentation provides the third-party perspective on operational aspects of immuno-oncology trials, including PDL1 stratification and biomarkers. Q2 Solutions presented as part of a collaborative talk with a panel discussion.

Q2 Solutions has a unique role in immuno-oncology drug development, with clinical laboratory services continually evolving to provide clear results that meet regulatory standards and drive confident decisions for customers.

Download this presentation to learn more.

Patrice Hugo, Ph.D., Chief Scientific Officer

Howard Grossberg, MD, Senior Medical Director, Oncology Center of Excellence, IQVIA
Jeff Hodge, VP, Development Solutions, Oncology Center of Excellence, IQVIA

Related Services:
Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Biomarker Roadmap to Success

Develop a biomarker roadmap for a successful strategy in developing targeted therapies

The Power of the Central Laboratory for Immuno-Oncology Drug Development

Global Anatomic Pathology Solutions

Learn how we can advance your clinical trials

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

Immune repertoire profiling provides better outcomes for immuno-oncology development programs

Read More